Evidence map›Paper›PMID 35382534›Full record

ReviewEngineering in life sciences2022

Vascular implants - new aspects for in situ tissue engineering.

Cornelia Blume, Xenia Kraus, Sebastian Heene, Sebastian Loewner, Nils Stanislawski, Fabian Cholewa, Holger Blume

Open access · goldAbstract readReview
In one paragraph

Review in Engineering in life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cornelia BlumeInstitute for Technical Chemistry Leibniz University Hannover Hannover Germany.ORCID https://orcid.org/0000-0001-7487-4884
Xenia KrausInstitute for Technical Chemistry Leibniz University Hannover Hannover Germany.ORCID https://orcid.org/0000-0002-1186-5443
Sebastian HeeneInstitute for Technical Chemistry Leibniz University Hannover Hannover Germany.
Sebastian LoewnerInstitute for Technical Chemistry Leibniz University Hannover Hannover Germany.
Nils StanislawskiInstitute for Microelectronic Systems Leibniz University Hannover Hannover Germany.
Fabian CholewaInstitute for Microelectronic Systems Leibniz University Hannover Hannover Germany.
Holger BlumeInstitute for Microelectronic Systems Leibniz University Hannover Hannover Germany.
Leibniz University Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional synthetic vascular grafts require ongoing anticoagulation, and autologous venous grafts are often not available in elderly patients. This review highlights the development of bioartificial vessels replacing brain-dead donor- or animal-deriving vessels with ongoing immune reactivity. The vision for such bio-hybrids exists in a combination of biodegradable scaffolds and seeding with immune-neutral cells, and here different cells sources such as autologous progenitor cells or stem cells are relevant. This kind of in situ tissue engineering depends on a suitable bioreactor system with elaborate monitoring systems, three-dimensional (3D) visualization and a potential of cell conditioning into the direction of the targeted vascular cell phenotype. Necessary bioreactor tools for dynamic and pulsatile cultivation are described. In addition, a concept for design of vasa vasorum is outlined, that is needed for sustainable nutrition of the wall structure in large caliber vessels. For scaffold design and cell adhesion additives, different materials and technologies are discussed. 3D printing is introduced as a relatively new field with promising prospects, for example, to create complex geometries or micro-structured surfaces for optimal cell adhesion and ingrowth in a standardized and custom designed procedure. Summarizing, a bio-hybrid vascular prosthesis from a controlled biotechnological process is thus coming more and more into view. It has the potential to withstand strict approval requirements applied for advanced therapy medicinal products.

Indexed as

3D printingbioreactor designtissue engineeringvascular implants

Identifiers

PMID35382534
PMCPMC8961049
OpenAlexW4206316689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.